Physician profile
Rundeep Gadh
NPI 1407095615
$685.87
in general payments reported to CMS, 2019-2025
12 companies · $69.33 in 2025
The $69.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $98.67 · 2022: $79.72 · 2024: $13.33 · 2025: $69.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $176.69 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $167.40 | 2019-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.71 | 2019-2022 | |
| Pfizer INC. | $55.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.53 | 2019 | |
| Merck Sharp & Dohme LLC | $31.28 | 2019 | |
| Abbott Laboratories | $31.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.31 | 2019 | |
| Astellas Pharma US INC | $18.42 | 2019 | |
| Kaleo, INC. | $14.10 | 2019 | |
| Amgen INC. | $14.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rundeep Gadh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.